Dicot Pharma AB (NGM: DICOT)
Sweden
· Delayed Price · Currency is SEK 0.190
-0.017 (-8.31%)
At close: Sep 6, 2024
Dicot Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Other Revenue | - | - | - | - | - | 0.62 | Upgrade
|
| Revenue | - | - | - | - | - | 0.62 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | - | 38.72% | Upgrade
|
| Gross Profit | - | - | - | - | - | 0.62 | Upgrade
|
| Selling, General & Admin | 52.24 | 45.03 | 31.67 | 27.13 | 17.52 | 13.95 | Upgrade
|
| Other Operating Expenses | -0.05 | -0 | 0.13 | 0.11 | 0.04 | 0 | Upgrade
|
| Operating Expenses | 52.19 | 45.04 | 31.8 | 27.25 | 17.56 | 13.96 | Upgrade
|
| Operating Income | -52.19 | -45.04 | -31.8 | -27.25 | -17.56 | -13.33 | Upgrade
|
| Interest Expense | -0.07 | -0.07 | -0.03 | -0 | -0.01 | -0.07 | Upgrade
|
| Interest & Investment Income | 1.28 | 0.91 | - | 0 | 0.01 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.03 | 0.03 | 0.08 | 0.05 | 0.02 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -50.95 | -44.16 | -31.76 | -27.2 | -17.54 | -13.4 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.03 | - | - | Upgrade
|
| Pretax Income | -50.94 | -44.16 | -31.76 | -27.17 | -17.54 | -13.4 | Upgrade
|
| Net Income | -50.94 | -44.16 | -31.76 | -27.17 | -17.54 | -13.4 | Upgrade
|
| Net Income to Common | -50.94 | -44.16 | -31.76 | -27.17 | -17.54 | -13.4 | Upgrade
|
| Shares Outstanding (Basic) | 742 | 530 | 120 | 64 | 29 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 742 | 530 | 121 | 64 | 29 | 10 | Upgrade
|
| Shares Change (YoY) | 179.40% | 336.53% | 89.21% | 124.32% | 187.81% | 56.75% | Upgrade
|
| EPS (Basic) | -0.07 | -0.08 | -0.26 | -0.42 | -0.61 | -1.35 | Upgrade
|
| EPS (Diluted) | -0.07 | -0.08 | -0.26 | -0.42 | -0.61 | -1.35 | Upgrade
|
| Free Cash Flow | -51.76 | -45.23 | -29.71 | -25.87 | -16.29 | -14.76 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.09 | -0.24 | -0.40 | -0.57 | -1.49 | Upgrade
|
| Gross Margin | - | - | - | - | - | 100.00% | Upgrade
|
| Operating Margin | - | - | - | - | - | -2135.66% | Upgrade
|
| Profit Margin | - | - | - | - | - | -2145.94% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | - | -2364.31% | Upgrade
|
| EBITDA | -52.18 | -45.03 | -31.79 | -27.24 | -17.56 | - | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0 | - | Upgrade
|
| EBIT | -52.19 | -45.04 | -31.8 | -27.25 | -17.56 | -13.33 | Upgrade
|
| Revenue as Reported | 0.24 | 0.23 | 0.12 | 0.08 | 0.02 | 0.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.